Dr. Jagannath On Mechanism Of Action Of Selinexor In Myeloma

Dr. Jagannath on Mechanism of Action of Selinexor in Myeloma

Dr. Jagannath on the Safety Profile of Selinexor in Multiple Myeloma

Dr. Parekh on the Mechanism of Action of Selinexor in Myeloma

Dr. Jagannath Discusses Advances in the Management of Relapsed Multiple Myeloma

Targeted Oncology

Dr.Jagannath on Role for Two-Drug Combinations, Carfilzomib Triplet in Multiple Myeloma

Dr. Jagannath on Potential of Immunotherapy in Multiple Myeloma

Mechanism of Action of Selinexor for the Treatment of Multiple Myeloma

Targeted Oncology

Dr. Jagannath on CAR T-Cell Therapy for Multiple Myeloma

Dose reduction of selinexor in combination with bortezomib and dexamethasone in multiple myeloma

VJHemOnc – Video Journal of Hematology & HemOnc

Dr. Jagannath on the Importance of Biology in Multiple Myeloma

Dr. Jagannath on Sequencing Therapies for Patients With Multiple Myeloma

Dr. Jagannath on Next-Generation Approaches in Multiple Myeloma

Dr. Jagannath Discusses the STORM and STOMP Trials for Patients With Multiple Myeloma

Targeted Oncology

Dr. Jagannath on Targeted Therapies and Stem Cell Transplantation in Multiple Myeloma

Targeted Oncology

Dr. Jagannath on Immunotherapy in Multiple Myeloma

How does selinexor fit into the treatment algorithm for myeloma?

VJHemOnc – Video Journal of Hematology & HemOnc

Dr. Jagannath on Treatment Advances in Transplant-Ineligible Patients With Myeloma

Copy of Dr. Parekh on the Mechanism of Action of Selinexor in Myeloma

Dr. Jagannath on Pomalidomide in Multiple Myeloma

The role of selinexor in the context of novel immune therapies in R/R multiple myeloma

VJHemOnc – Video Journal of Hematology & HemOnc